Cannabix Marijuana Breath Test Featured on the Cover of AlcoPro’s 2026 Product Catalog
Rhea-AI Summary
Cannabix Technologies (OTCID: BLOZF) announced its Marijuana Breath Test (MBT) will appear on the cover of AlcoPro 2026 product catalogue, which will be distributed to more than 85,000 businesses in the U.S. and internationally, including law enforcement and corrections.
Cannabix and AlcoPro are collaborating on pre-launch U.S. marketing for the MBT. The MBT combines Cannabix’s Breath Collection Unit and Breath Cartridge for non-invasive breath sampling intended for LC-MS analysis. Cannabix also highlights a strategic partnership with Omega Laboratories, a forensic drug-testing provider with over 25 years of certifications and experience.
Positive
- Catalogue reach: distribution to >85,000 businesses
- U.S. marketing partnership with established supplier AlcoPro
- Technical integration: Breath Collection Unit + Breath Cartridge for LC-MS
Negative
- Product is in pre-launch marketing; no commercial sales disclosed
- No financial guidance or revenue impact quantified from catalogue exposure
News Market Reaction – BLOZF
In the Jan 22 session, BLOZF gained 0.68%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
VANCOUVER, British Columbia, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) a developer of marijuana and alcohol breath-testing devices, is pleased to announce that its Marijuana Breath Test (“MBT”) will be featured on the cover of the 2026 AlcoPro Inc. product catalogue (see Figure 1). AlcoPro Inc. (“AlcoPro”), based in Knoxville, TN, is a leading U.S. supplier of professional drug and alcohol testing instruments, kits, and supplies, serving customers since 1982. The 2026 AlcoPro product catalogue will be distributed to more than 85,000 businesses across the United States and internationally including law enforcement and the corrections segment.
Figure 1. Cannabix Technologies Inc. Marijuana Breath Test featured on cover of 2026 AlcoPro, Inc. product catalog
Cannabix and AlcoPro have been working closely together on pre-launch marketing activities for the MBT primarily in the U.S. market.
The Marijuana Breath Test (MBT) system brings together Cannabix’s proprietary Breath Collection Unit and Breath Cartridge technologies to capture and preserve non-invasive breath samples for gold-standard LC-MS analysis. Cannabix’s strategic partnership with Omega Laboratories Inc.—a global leader in forensic drug testing for more than 25 years—adds world-class expertise, backed by multiple federal and international certifications and decades of innovation in drug detection.
Brian Terry, Director of Business Development of AlcoPro stated, “We are exciting about our growing relationship with Cannabix Technologies, and the upcoming availability of the MBT to our clients. We’re moving beyond traditional testing tools and leaning into advanced technologies that deliver the accuracy today’s workplaces demand. As safety challenges shift, staying ahead with solutions that proactively reduce risk is essential to protecting employees.”
About AlcoPro, Inc.
Since 1982, AlcoPro has been a trusted leader in drug and alcohol testing solutions for employers, healthcare professionals, law enforcement, and substance abuse specialists. Known for reliable instruments like market-leading breathalyzers, AlcoPro also offers innovative online training with interactive tools to enhance knowledge retention. With a comprehensive product catalog, easy online ordering, and expert support, AlcoPro makes workplace testing simple, accurate, and professional. Learn more at www.AlcoPro.com.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a developer of marijuana and alcohol breathalyzer technologies for law enforcement, workplaces and laboratories. Cannabix is developing delta-9 THC and alcohol screening devices. Delta-9 THC is the primary psychoactive ingredient in cannabis. Breath testing for delta-9 THC would allow employers and law enforcement to identify recent marijuana use. Cannabix is the developer of its Breath Logix Series of breath alcohol detection devices for employers and a range of other settings.
We seek Safe Harbor.
On behalf of the Board of Directors
“Rav Mlait”
CEO
Cannabix Technologies Inc.
For further information, contact the Company at info@cannabixtechnologies.com
Cautionary Statement Regarding Forward-Looking Statements
This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates," "plan," "continue," "expect," "project," "intend," "believe," "anticipate," "estimate," "may," "will," "potential," "proposed," "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include, but are not limited to, statements relating to: the achievement of any or all of the goals and aims as described in this news release; final development of a commercial or prototype product(s); the successful trial or pilot of company technologies; the commercialization of the Company's products; the negotiation and potential entry into additional agreements with existing and new partners; and the completion of future financings. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information. Important factors that could cause actual results to differ materially from those expressed in the forward-looking information include (but are note limited to): adverse market conditions; risks regarding protection of proprietary technology; the ability of the Company to complete future financings; the ability of the Company to develop and market its future product; risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition; that partners may not complete all or any of the milestones as contemplated strategic partnership agreements; that the CSE may not approve the issuance of the securities; that the Company’s development of breathalyzer technology will provide any benefit to the Company; there is no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials; there is no assurance that the Company will enter into any partnerships to advance any of its corporate initiatives or technologies; there is no assurance that any “patent pending” or “provisional patents” technologies licensed by the Company or owned by the Company will receive patent status by regulatory authorities; the Company is not currently selling breathalyzers and there is no assurance that the Company ever will; and other factors beyond the control of the Company. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d2807785-4c17-4e58-84d7-8fa78fc3e398
